ErbB2/HER2 Antibody (0.N.211): sc-71667

Neu Antibody (0.N.211) is a mouse monoclonal IgG1 antibody that detects Neu in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Neu, also known as ErbB-2 or HER2, is a member of the epidermal growth factor receptor (EGFR) family, which plays a critical role in cell signaling pathways that regulate cell growth, survival, and differentiation. anti-Neu antibody (0.N.211) recognizes protein interactions with other EGFR family members, such as ErbB-3, which enhances signaling cascades leading to increased tumor cell motility and invasion, as well as modulation of cell cycle checkpoints and apoptotic responses. Notably, amplification and overexpression of Neu are observed in 20-30% of breast carcinomas, making Neu a significant biomarker for disease prognosis and a potential target for therapeutic interventions. Neu monoclonal antibody (0.N.211) provides a valuable tool for researchers investigating Neu′s role in cancer biology and therapeutic development, enabling the exploration of protein interactions and functions in various cellular contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ErbB2/HER2 Antibody (0.N.211) References:

1. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion.  |  Khoury, H., et al. 2005. Mol Biol Cell. 16: 550-61. PMID: 15548598
2. Inhibition of HER-2(neu/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia.  |  Wilson, SJ., et al. 2006. Biochim Biophys Acta. 1762: 647-55. PMID: 16797938
3. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.  |  Ursini-Siegel, J., et al. 2007. Mol Cell Biol. 27: 6361-71. PMID: 17636013
4. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.  |  Raven, JF., et al. 2011. Cell Cycle. 10: 794-804. PMID: 21311224
5. Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors.  |  Wang, Q., et al. 2014. Int J Oncol. 44: 1277-83. PMID: 24452693
6. A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines.  |  Omenn, GS., et al. 2014. J Proteomics. 107: 103-12. PMID: 24802673
7. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.  |  Sriram, R., et al. 2015. Breast Cancer Res. 17: 7. PMID: 25592291
8. Pparγ1 Facilitates ErbB2-Mammary Adenocarcinoma in Mice.  |  Jiao, X., et al. 2021. Cancers (Basel). 13: PMID: 33946495
9. LASP-1 interacts with ErbB2 in ovarian cancer cells.  |  Sidhanth, C., et al. 2022. Biochem J. 479: 23-38. PMID: 34881777
10. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.  |  Kang, KS., et al. 1998. Mol Carcinog. 21: 225-33. PMID: 9585252

The preferred antibody is Antibody (): sc-8.